Collaborative Seamless Care in Oncology : Measure and Reinforce Safety and Adherence to Oral Cancer Treatment
Collaborative and Seamless Care in Oncology : a Study in Primary Care to Measure and Reinforce Safety and Adherence to Oral Cancer Treatment
1 other identifier
observational
43
1 country
1
Brief Summary
The purpose of this study is to implement a support interdisciplinary program(oncologists, pharmacists, physicians, nurses, leagues against cancer) of medication adherence to oral oncology treatments. The aim is to ensure continuity of care between professionals,effectiveness of treatment and patient safety.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jul 2010
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2010
CompletedFirst Submitted
Initial submission to the registry
June 3, 2011
CompletedFirst Posted
Study publicly available on registry
June 10, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2014
CompletedNovember 22, 2022
November 1, 2022
1.4 years
June 3, 2011
November 21, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in Medication adherence
MEMS data, completed by informations given in motivational interviewing
3 months, 6 months, 9 months, 12 months
Secondary Outcomes (4)
Program implementation
1 year
Oncologists, nurses, pharmacists and patients satisfaction
1 year
Effect of Adverse Drug Reaction (ADR) on medication adherence
1 year
Change in Adverse Drug Reaction (ADR)
3 months, 6 months, 9 months, 12 months
Study Arms (1)
Study population
Adults (18 years old or more) with one of the following oral oncology treatments: letrozole, exémestane, imatinib, sunitinib, nilotinib, evérolimus, déférasirox
Eligibility Criteria
Patient with cancer treated by oral medication in swiss-romande hospitals and private oncologists, and enrolled in the adherence program in one of the thirty studies pharmacies.
You may qualify if:
- years and older
- Treated for a cancer with oral medication (letrozol, exemestan,imatinib, sunitinib, nilotinib, everolimus, deferasirox)
- French speaking
You may not qualify if:
- \- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Policlinique Médicale Universitaire and Centre pluridisciplinaire d'oncologie, CHUV
Lausanne, Canton of Vaud, 1010, Switzerland
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Bugnon Olivier, Professor
Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland
- STUDY CHAIR
Lüthi François, Dr
Clinique Bois-Cerf, Lausanne
- PRINCIPAL INVESTIGATOR
Schneider Marie-Paule, PhD
Policlinique Medicale Universitaire
- PRINCIPAL INVESTIGATOR
Chevaux Bernard, Dr
Centre Hospitalier Universitaire Vaudois
- PRINCIPAL INVESTIGATOR
Troxler Stéphanie, PhD Student
Policlinique Medicale Universitaire
- PRINCIPAL INVESTIGATOR
Leila Achtari, MD
Centre Hospitalier Univeristaire Vaudois
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Dr
Study Record Dates
First Submitted
June 3, 2011
First Posted
June 10, 2011
Study Start
July 1, 2010
Primary Completion
December 1, 2011
Study Completion
September 1, 2014
Last Updated
November 22, 2022
Record last verified: 2022-11